Our Mission
To Bring Those Tracking the Weight Loss Market The Latest Industry News and Company Developments, Marketdata Commentary and Opinions. To Provide An Ongoing Forum for Discussion and Feedback for Those Working in The Weight Loss Field.
The Most Comprehensive Study About The U.S. Weight Loss Market–Since 1989
The U.S. Weight Loss & Diet Control Market
March 2023 427 Pages 160 tables/charts Price: $1,995
The $75 billion U.S. weight loss market grew nearly 15% last year from the depressed level of 2020. Most segments of the market have recovered from the Covid-19 pandemic and recession. The big story of 2022 has been the soaring demand for new obesity drugs such as Wegovy and Saxenda, with more new drugs coming soon. The market may be entering a new era of medical approaches. Even Weight Watchers is now providing a medical plan.
The frozen diet entrees market and diet soft drinks have shown surprising strength, but the health clubs industry was devasted by the pandemic and emerges as a smaller sector. Supply chain disruptions affected the MLM market for meal replacements into 2021 and 2022, tamping down growth for Herbalife and Medifast. The ranks of commercial weight loss centers have been thinned out, and chains had to pivot to virtual client meetings and drop shipping of
products.
Do-it-yourself plans still abound as consumers use free diet & fitness apps. Many untapped niches still exist. This is a completely revised and updated analysis of Marketdata’s best-selling biennial study about the U.S. weight loss market. This is the most comprehensive investigation of the U.S. weight loss market published by anyone worldwide.
Covered… dollar value & growth rates of all major weight loss market segments (early 1980s to 2022 and 2023 & 2027 forecasts), latest market trends and developments, status reports for: diet soft drinks, artificial sweeteners, health clubs, commercial diet center chains, multi-level marketing diet plans, retail meal replacements & weight loss supplements, medical programs (weight loss surgery, MDs, hospitals/clinic programs, Rx diet drugs, bariatricians, VLCD programs), low-cal frozen entrees, and the diet books & exercise DVDs market.
New for this edition:
- Effects of the Pandemic on operations & revenues for all market segments, analysis of the recovery
- How dieter behavior changed with the pandemic
- The skyrocketing market for Rx obesity drugs and MD programs
- 2022 market performance, 2023 & 2027 Forecasts
- The most popular diets today
- Ranking of the leading competitor companies
- Outlook for the 2023 diet season
- Why MLM is a major force in meal replacements sales, tough year in 2022
- The franchising slowdown.
Also included: 34-year revenue analysis of the market through past recessions and fad diet cycles, comprehensive dieter demographics, weight loss center franchising, and extensive national/state commercial centers’ operating ratios. Rankings & revenues of top commercial chains, brand sales, and a Reference Directory. Contains 34 in-depth competitor profiles for: Weight Watchers, Jenny Craig, NutriSystem, Medifast, Herbalife, Noom, Slim-Fast, Atkins Nutritionals, HMR, Optifast, Robard, Lindora Clinics, Slimgenics, Ideal Protein, Profile by Sanford, BeachBody, Metabolic Research, Smart For Life, Medi-Weightloss, Centers for Medical Weight Loss, Nuviva, JumptStart MD, Dr. G’s, more.
Report also sold by individual chapters at lower price. $99 Overview available.
Latest News
Telehealth Companies Offer Novo’s Wegovy pill
Jan. 6, 2026 Novo Nordisk launched the pill version of its popular obesity medication Wegovy on Monday Jan. 5. The firm aimed to capture patients with a cash-pay discount — $149 a month for the lowest starting doses of the medication through April 15. It’s also trying to onboard new patients through a growing number of telehealth providers. Novo’s direct-to-consumer patient portal, NovoCare, now includes links to seven telehealth companies that can prescribe its medication. The site says the providers,
FDA Approves Novo’s Wegovy Weight Loss Pill
Dec. 22, 2025 The U.S. Food and Drug Administration on Dec. 22 approved a pill version of Novo Nordisk’s weight-loss drug Wegovy, the first daily oral medication for obesity treatment. The once-daily tablet — called the Wegovy pill — is the “first and only” oral GLP-1 medicine, or glucagon-like peptide-1, receptor agonists, according to Novo Nordisk. “Wegovy pill is the next chapter in our decades-long GLP-1 experience—supported by the most affordable self-pay price to date in a GLP-1 for obesity,” Dave Moore, executive vice president
Novo Nordisk Lowers Weight Loss Drug Prices
Nov. 17, 2025 Due to increased competition in the weight loss market and intense pressure from President Trump, Novo Nordisk announced Monday that it is lowering prices for its blockbuster obesity and diabetes drugs for cash-paying patients. This is is the latest step in the firm’s efforts to provide discounts to Americans willing to buy medications directly from them and forgo insurance. Also, it’s another way Novo Nordisk is seeking to fend off compounding pharmacies that are cutting into the
Trump Cuts Deal To Lower Weight Loss Drug Prices
Nov. 6, 2025 CNBC reported today that President Donald Trump announced deals with Eli Lilly and Novo Nordisk and Eli Lilly toslash the prices of some of their obesity drugs, including upcoming pills, in a landmark effort to expand access to the costly blockbuster treatment. The agreements will cut prices of so-called GLP-1 drugs for Medicare and Medicaid beneficiaries in 2026 and offer the treatments directly to consumers at a discount on a website the Trump administration is launching in
Marketdata weight loss reports have been quoted by..